强生达雷妥尤单抗进入“百亿美元俱乐部”几乎已无悬念之际，蓄势已久的CD38药物终于在2025年开年展现出了燎原态势。 2025年的第二周，CD38靶点 ...

The CD34+CD38− cells, isolated from acute myeloid leukemia (AML), were shown to be enriched leukemic stem cells (LSC). We isolated the CD34+CD38− cell fraction from AML and compared their gene ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

信达/康方/君实之后，恒瑞PCSK9单抗获批上市 赛诺菲抗CD38单抗在华上市，用于多发性骨髓瘤 1月9日，赛诺菲宣布旗下抗CD38单抗 ...

赛诺菲今日宣布，旗下抗CD38单抗赛可益 ® （艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA）批准，用于与泊马度胺和地塞米松联合用药 ...

1月10日，康诺亚宣布，就潜在同类最优的靶向CD38人源化单克隆抗体CM313与Timberlyne Therapeutics达成独家授权许可协议。 CM313是由康诺亚自主研发的靶向 ...

中国网财经1月9日讯 赛诺菲今日宣布，旗下抗CD38单抗赛可益(艾沙妥昔单抗注射液)获得国家药品监督管理局(NMPA)批准，用于与泊马度胺和地塞米松 ...

Notably, this approach did not damage healthy early blood stem cells or immune cells in human and AML mouse models. When leukemia infiltrates the bone marrow, it generates CD38-positive abnormal ...

BN-CD38 eradicates acute myeloid leukemia (AML) by inducing the expression of its own therapeutic target and by expanding and redirecting autologous T-cells against AML blasts and leukemia stem cells.

每经AI快讯，1月9日，据赛诺菲中国微信公众号消息，赛诺菲今日宣布，旗下抗CD38单抗赛可益（艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA ...